System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT04935853 on ClinicalTrials.gov

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Official title: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL

  • Sponsor: GERCOR (France)
  • Enrollment: 1350 (Estimated)
  • Study start: 2022-05-23 (Actual)
  • Primary completion: 2030-06-01 (Estimated)
  • Study completion: 2040-06-01 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.

Conditions

  • Biliary Tract Cancer

Primary Outcome Measures

  • Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months (Up to 10 years from the date of initial cancer diagnosis (or until death if it occurs before 10 years))
    Identification of clinical and tumor predictive factors of overall survival (OS) (prognostic markers) in patients with advanced bile duct cancer (BDC). OS defined as a period between the start of treatment and death, whatever the cause.

Countries

France

Locations and Investigators

  • CHU Hôpital Sud Amiens, Amiens, France (Recruiting)
  • CHU Angers, Angers, France (Recruiting)
    • Carole VITELLIUS, MD
  • CHU Besançon, Besançon, France (Recruiting)
    • Angélique VIENOT, MD
  • Hôpital Avicenne, Bobigny, France (Recruiting)
    • Jean Charles NAULT, MD
  • CHU - Henri Mondor, Créteil, France (Recruiting)
    • Christophe TOURNIGAND, MD
  • CHU Dijon, Dijon, France (Recruiting)
    • Sylvain MANFREDI, MD
  • CHU Grenoble, Grenoble, France (Recruiting)
    • Gaël ROTH, MD
  • CHU Lille, Lille, France (Recruiting)
    • Anthony TURPIN, MD
  • Centre Léon Bérard, Lyon, France (Recruiting)
    • Mathieu SARABI, MD
  • Hôpital Croix Rousse, Lyon, France (Recruiting)
    • Marielle GUILLET, MD
  • Hôpital Edouard Herriot, Lyon, France (Recruiting)
    • Thomas WALTER, MD
  • Hôpital Privé Jean Mermoz, Lyon, France (Recruiting)
    • Pascal ARTRU, MD
  • Institut Paoli Calmette, Marseille, France (Recruiting)
    • Brice CHANEZ, MD
  • CHU Saint Eloi Montpellier, Montpellier, France (Recruiting)
    • Eric ASSENAT, MD
  • CHR Orléans, Orléans, France (Recruiting)
    • Jean Paul LAGASSE, MD
  • Groupe Hospitalier Pitié Salpêtrière, Paris, France (Recruiting)
    • Jean Baptiste BACHET, MD
  • Hôpital Ambroise Paré, Paris, France (Recruiting)
    • Aude GUILLEMIN, MD
  • Hôpital Cochin, Paris, France (Recruiting)
    • Romain CORIAT, MD
  • Hôpital Saint Antoine, Paris, France (Recruiting)
    • Raphaël COLLE, MD
  • Hôpital Saint Louis, Paris, France (Recruiting)
    • Nelson LOURENCO, MD
  • Institut Mutualiste Montsouris, Paris, France (Recruiting)
    • Christophe LOUVET, MD
  • Hôpital Haut Lévêque, Pessac, France (Recruiting)
    • Jean François BLANC, MD
  • CHU Poitiers, Potiers, France (Recruiting)
  • Hôpital Robert Debré -CHU Reims, Reims, France (Recruiting)
    • Alexandra HEURGUE, MD
  • Centre Eugène Marquis, Rennes, France (Recruiting)
  • CHU Rouen Charles Nicolle, Rouen, France (Recruiting)
  • Institut Curie, Saint-Cloud, France (Recruiting)
    • Cindy NEUZILLET, MD
  • CHU Saint Etienne, Saint-Étienne, France (Recruiting)
    • Nicolas WILLET, MD
  • CHU Rangueil, Toulouse, France (Recruiting)
    • Nadim FARES, MD
  • CHU Tours, Tours, France (Recruiting)
    • Thierry LECOMTE, MD
  • CHRU Nancy Site Brabois, Vandœuvre-lès-Nancy, France (Recruiting)
    • Marie MULLER, MD
  • Institut Gustave Roussy, Villejuif, France (Recruiting)
    • Antoine HOLLEBECQUE, MD

Study Officials